

Mannich Reaction Mediated Derivatization of Chromones and Their Biological Evaluations as Putative Multipotent Ligands for the Treatment of Alzheimer's Disease

Naveen Kumar¹, Kailash Jangid^{1,2}, Vinay Kumar¹, Bharti Devi¹, Tania Arora³, Jayapriya Mishra⁴, Vijay Kumar¹, Ashish Ranjan Dwivedi^{2,5}, Jyoti Prakash³, Jasvinder Singh Bhatti⁴ and Vinod Kumar^{1*}

¹*Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, Central University of Punjab, Bathinda, Punjab, India-151401.*

²*Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India-151401.*

³*Department of Zoology, Central University of Punjab, Bathinda, Punjab, India-151401.*

⁴*Laboratory of Translational Medicine and Nanotherapeutics, Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India-151401.*

⁵*Gitam School of Pharmacy, Hyderabad, Telangana, 502329, India.*

Corresponding author

***Prof. (Dr) Vinod Kumar**

Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, Central University of Punjab, Bathinda, Punjab, India-151401.

E-mail: vpathania18@gmail.com; vinod.kumar@cup.edu.in

Phone No. +911642864214

Conflict of Interest Statement: Authors declare no potential conflict of interest.

Chemistry

General procedure for the synthesis of hydroxy chromone intermediates

A mixture of 2-Hydroxyacetophenone (1 equiv.), respective hydroxy-benzaldehyde (1 equiv.), and iodine (1 equiv.) were taken in a sealed tube in PEG-400 as solvent and heated at 140 °C for 4 to 7 h. Completion of the reaction was checked by thin-layer chromatography. On completion of the reaction, it was cooled to room temperature, iodine was quenched with 10 % sodium thiosulphate solution and extracted with ethyl acetate. The crude product was purified on silica gel by column chromatography using pet. ether/ethyl acetate (3:1 to 6:1) as eluent to give the desired product (70-84 % yield).

General procedure for the synthesis of Mannich intermediates

A mixture of paraformaldehyde (7 mmol) and secondary amines (3 mmol) were kept on heating at 80 °C for 1 h in ethanol. The synthesized chromone derivative (1 mmol) dissolved in ethanol was mixed to the above solution of imine. The reaction mixture was heated at 80 °C for 5-7 h to give the Mannich product as intermediate. Progress of the reaction was monitored using TLC plate. After completion of the reaction, ethanol was evaporated and water was added to the crude product. Aqueous layer was extracted with ethyl acetate thrice. Organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under vacuum using a rotary evaporator. Crude product was used for next step after column chromatography to purify the compounds using ethyl acetate-pet ether as eluent.

General procedure for the synthesis of *O*-alkylated chromone derivatives

To the solution of hydroxy-substituted Mannich intermediates (1 mmol) solubilized in minimum amount of DMF, alkyl halide (1.1 mmol) and K₂CO₃ (2.2 mmol) was added. The reaction mixture (RM) was heated at 80 °C and progress of the reaction was monitored using TLC plate. After completion of the reaction, water was added to the crude product. Aqueous layer was extracted with ethyl acetate thrice. Organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under vacuum using a rotary evaporator. The crude product was purified through column chromatography using acetone-pet ether as eluent to get the desired product. HRMS and NMR analysis was done for the characterization of synthesized compounds.

Characteristic spectral data of the products

2-(3-methoxy-5-(morpholinomethyl)-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-1)

White solid, 72 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6$ Hz, 1.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.61 (d, $J= 1.8$ Hz, 1H), 7.59 (d, $J= 8.4$ Hz, 1H), 7.43 (t, $J= 7.2$ Hz, 1H), 7.35 (d, $J= 1.8$ Hz, 1H), 6.79 (s, 1H), 4.15 (t, $J= 6.0$ Hz, 2H), 3.95 (s, 3H), 3.73 (t, $J= 4.8$ Hz, 4H), 3.61 (s, 2H), 2.52 (s, 4H), 2.49 (td, $J= 2.4$ Hz, 4.8 Hz, 2H), 2.03 (quintet, $J= 6.0$ Hz, 2H), 1.99 (t, 2.4 Hz, 1H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.3, 163.3, 156.2, 153.1, 149.9, 133.6, 132.6, 127.0, 125.7, 125.2, 123.9, 121.1, 118.1, 108.9, 107.3, 83.8, 71.6, 68.8, 67.0, 56.9, 55.9, 53.7, 29.2, 15.2. HRMS: m/z [M + H] $^+$ for $\text{C}_{26}\text{H}_{27}\text{NO}_5$, Calculated 434.1962; observed 434.1972.

2-(3-methoxy-5-(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-2)

Off-white solid, 66 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.6$ Hz, 1.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.63 (d, $J= 1.8$ Hz, 1H), 7.59 (d, $J= 7.8$ Hz, 1H), 7.42-7.45 (m, 1H), 7.36 (d, $J= 1.8$ Hz, 1H), 6.80 (s, 1H), 4.84 (d, $J= 2.4$ Hz, 2H), 3.97 (s, 3H), 3.73 (t, $J= 4.8$ Hz, 4H), 3.68 (s, 2H), 2.54 (s, 4H), 2.48 (t, $J= 2.4$ Hz, 1H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.3, 163.2, 156.2, 153.0, 148.2, 133.7, 133.5, 127.7, 125.7, 125.2, 123.9, 120.8, 118.1, 108.8, 107.4, 79.1, 75.5, 67.1, 60.2, 57.1, 56.0, 53.6. HRMS: m/z [M + H] $^+$ for $\text{C}_{24}\text{H}_{23}\text{NO}_5$, Calculated 406.1649; observed 406.1655.

2-(4-(but-3-yn-1-yloxy)-3-methoxy-5-(morpholinomethyl)phenyl)-4H-chromen-4-one (NS-3)

White solid, 69 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.0$ Hz, 4.2 Hz, 1H), 7.69-7.72 (m, 1H), 7.59-7.60 (m, 2H), 7.42-7.45 (m, 1H), 7.35 (d, $J= 1.8$ Hz, 1H), 6.79 (s, 1H), 4.21 (t, $J= 6.6$ Hz, 2H), 3.96 (s, 3H), 3.73 (t, $J= 4.8$ Hz, 4H), 3.64 (s, 2H), 2.70 (td, $J= 4.2$ Hz, 3.0 Hz, 2H), 2.53 (s, 4H), 2.05 (t, $J= 3.0$ Hz, 1H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.3, 163.2, 156.2, 153.0, 149.4, 133.7, 132.6, 127.2, 125.7, 125.2, 123.9, 121.1, 118.1, 109.0, 107.3, 80.9, 71.1, 69.8, 67.0, 57.0, 56.0, 53.6, 20.3. HRMS: m/z [M + H] $^+$ for $\text{C}_{25}\text{H}_{25}\text{NO}_5$, Calculated 420.1805; observed 420.1833.

2-(3-methoxy-5-(piperidin-1-ylmethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-4)

Yellowish solid, 66 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (d, $J= 8.4$ Hz, 1H), 7.70 (t, $J= 7.2$ Hz, 1H), 7.66 (s, 1H), 7.59 (d, $J= 8.4$ Hz, 1H), 7.42 (t, $J= 7.2$ Hz, 1H), 7.34 (s, 1H), 6.81 (s, 1H),

4.84 (d, $J= 1.8$ Hz, 2H), 3.96 (s, 3H), 3.67 (s, 2H), 2.51 (s, 1H), 2.48 (s, 4H), 1.60 (quintet, $J= 5.4$ Hz, 4H), 1.45 (s, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.4, 163.3, 156.2, 152.9, 148.2, 133.7, 127.6, 125.7, 125.2, 123.9, 121.1, 118.1, 108.6, 107.3, 79.1, 75.4, 60.2, 57.2, 56.0, 54.4, 25.9, 24.2. HRMS: m/z [M + H]⁺ for $\text{C}_{25}\text{H}_{25}\text{NO}_4$, Calculated 404.1856; observed 404.1855.

2-(3-methoxy-4-(pent-4-yn-1-yloxy)-5-(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-5)

White solid, 78 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.6$ Hz, 1.2 Hz, 1H), 7.69-7.71 (m, 1H), 7.63 (d, $J= 2.4$ Hz, 1H), 7.59 (d, $J= 8.4$ Hz, 1H), 7.41-7.44 (m, 1H), 7.33 (d, $J= 2.4$ Hz, 1H), 6.80 (s, 1H), 4.13 (t, $J= 6.6$ Hz, 2H), 3.94 (s, 3H), 3.56 (s, 2H), 2.49 (td, $J= 4.2$ Hz, 3.0 Hz, 2H), 2.43 (s, 4H), 2.02 (quintet, $J= 7.2$ Hz, 2H), 1.98 (t, $J= 2.4$ Hz, 1H), 1.59 (quintet, $J= 5.4$ Hz, 4H), 1.45 (s, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.4, 163.5, 156.2, 153.0, 149.8, 133.7, 133.6, 126.8, 125.7, 125.1, 123.9, 121.2, 118.1, 108.6, 107.2, 83.9, 71.6, 68.6, 57.2, 55.9, 54.6, 29.2, 26.1, 24.3, 15.2. HRMS: m/z [M + H]⁺ for $\text{C}_{27}\text{H}_{29}\text{NO}_4$, Calculated 432.2169; observed 432.2173.

2-(3-ethoxy-5-(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-6)

White solid, 73 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (d, $J= 7.8$ Hz, 1H), 7.69-7.72 (m, 1H), 7.61 (s, 1H), 7.58 (d, $J= 8.4$ Hz, 1H), 7.41-7.45 (m, 1H), 7.34 (s, 1H), 6.78 (s, 1H), 4.87 (d, $J= 0.6$ Hz, 2H), 4.18 (q, $J= 7.2$ Hz, 2H), 3.73 (t, $J= 4.2$ Hz, 4H), 3.68 (s, 2H), 2.53 (s, 4H), 2.47 (t, $J= 2.4$ Hz, 1H), 1.52 (t, $J= 7.2$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.3, 163.2, 156.2, 152.2, 148.4, 133.7, 133.4, 127.6, 125.7, 125.2, 123.9, 120.7, 118.0, 109.8, 107.4, 79.2, 75.4, 67.1, 64.6, 60.1, 57.1, 53.6, 14.8. HRMS: m/z [M + H]⁺ for $\text{C}_{25}\text{H}_{25}\text{NO}_5$, Calculated 420.1805; observed 420.1803.

2-(4-(but-3-yn-1-yloxy)-3-ethoxy-5-(morpholinomethyl)phenyl)-4H-chromen-4-one (NS-7)

Yellowish solid, 64 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.0$ Hz, 1.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.59 (d, $J= 7.8$ Hz, 2H), 7.41-7.45 (m, 1H), 7.34 (d, $J= 2.4$ Hz, 1H), 6.78 (s, 1H), 4.23 (t, $J= 6.6$ Hz, 2H), 4.17 (q, $J= 7.2$ Hz, 2H), 3.73 (t, $J= 4.2$ Hz, 4H), 3.64 (s, 2H), 2.71 (td, $J= 4.2$ Hz, 2.4 Hz, 2H), 2.53 (s, 4H), 2.04 (t, $J= 3.0$ Hz, 1H), 1.52 (t, $J= 6.6$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.4, 163.3, 156.2, 152.2, 149.6, 133.7, 132.5, 127.1, 125.7, 125.2, 123.9, 121.0, 118.0, 110.0, 107.3, 81.0, 71.1, 69.8, 67.0, 64.6, 57.0, 53.6, 20.4, 14.8. HRMS: m/z [M + H]⁺ for $\text{C}_{26}\text{H}_{27}\text{NO}_5$, Calculated 434.1962; observed 434.1966.

2-(3-ethoxy-5-(morpholinomethyl)-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-8)

Off-white solid, 68 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.0$ Hz, 1.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.58-7.60 (m, 2H), 7.41-7.44 (m, 1H), 7.34 (dd, $J= 2.4$ Hz, 1H), 6.78 (s, 1H), 4.15-4.19 (m, 4H), 3.73 (t, $J= 4.8$ Hz, 4H), 3.60 (s, 2H), 2.52 (s, 4H), 2.49 (td, $J= 4.2$ Hz, 2.4 Hz, 2H), 2.03 (quintet, $J= 6.6$ Hz, 2H), 1.99 (t, $J= 3.0$ Hz, 1H), 1.52 (t, $J= 6.6$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.3, 163.4, 156.2, 152.3, 150.0, 133.6, 132.5, 126.9, 125.7, 125.2, 123.9, 121.0, 118.0, 109.9, 107.2, 83.8, 71.6, 68.8, 67.1, 64.5, 56.9, 53.7, 29.2, 15.3, 14.8. HRMS: m/z [M + H] $^+$ for $\text{C}_{27}\text{H}_{29}\text{NO}_5$, Calculated 448.2118; observed 448.2121.

2-(3-ethoxy-4-(pent-4-yn-1-yloxy)-5-(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-9)

Off-white solid, 69 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.0$ Hz, 1.8 Hz, 1H), 7.68-7.71 (m, 1H), 7.61 (d, $J= 7.58$, 1H), (dd, $J= 7.8$ Hz, 0.6 Hz, 1H), 7.40-7.43 (m, 1H), 7.32 (d, $J= 2.4$ Hz, 1H), 6.78 (s, 1H), 4.14-4.17 (m, 4H), 3.55 (s, 2H), 2.49 (td, $J= 4.8$ Hz, 2.4 Hz, 2H), 2.44 (s, 4H), 2.02 (quintet, $J= 6.0$ Hz, 2H), 1.99 (t, $J= 3.0$ Hz, 1H), 1.59 (quintet, $J= 5.4$ Hz, 4H), 1.51 (t, $J= 7.2$ Hz, 3H), 1.45 (s, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.4, 163.7, 156.3, 152.3, 150.0, 133.7, 133.6, 126.8, 125.7, 125.2, 124.0, 121.1, 118.1, 109.6, 107.2, 83.9, 71.6, 68.7, 64.5, 57.3, 54.7, 29.3, 26.1, 24.4, 15.4, 14.9. HRMS: m/z [M + H] $^+$ for $\text{C}_{28}\text{H}_{31}\text{NO}_4$, Calculated 446.2326; observed 446.2328.

2-(3,5-bis(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-10)

Off-white solid, 64 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.24 (dd, $J= 6.6$ Hz, 1.2 Hz, 1H), 7.87 (s, 2H), 7.70-7.74 (m, 1H), 7.60 (d, $J= 8.4$ Hz, 1H), 7.44 (t, $J= 7.2$ Hz, 1H), 6.81 (s, 1H), 4.93 (d, $J= 3.0$ Hz, 2H), 3.73 (t, $J= 4.8$ Hz, 8H), 3.64 (s, 4H), 2.58 (t, $J= 2.4$ Hz, 1H), 2.55 (s, 8H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.3, 163.0, 159.1, 156.2, 133.7, 133.0, 128.4, 127.6, 125.7, 125.3, 123.9, 118.1, 107.5, 79.1, 75.7, 67.0, 62.8, 57.7, 53.6. HRMS: m/z [M + H] $^+$ for $\text{C}_{28}\text{H}_{30}\text{N}_2\text{O}_4$, Calculated 475.2227; observed 475.2228.

2-(3,5-bis(morpholinomethyl)-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-11)

Off-white solid, 77 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.24 (dd, $J= 6.6$ Hz, 1.2 Hz, 1H), 7.93 (s, 2H), 7.70-7.73 (m, 1H), 7.60 (dd, $J= 7.8$ Hz, 0.6 Hz, 1H), 7.42-7.45 (m, 1H), 6.82 (s, 1H), 4.08 (t, $J= 6.6$ Hz, 2H), 3.74 (t, $J= 4.2$ Hz, 8H), 3.61 (s, 4H), 2.50-2.53 (m, 10H), 2.05 (quintet, $J= 6.6$ Hz, 2H), 2.03 (t, $J= 2.4$ Hz, 1H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.4, 163.3, 159.6, 156.2, 133.7,

132.4, 128.0, 127.2, 125.7, 125.2, 123.9, 118.1, 107.3, 83.6, 72.9, 69.3, 67.0, 57.1, 53.7, 29.0, 15.2. HRMS: m/z [M + H]⁺ for C₃₀H₃₄N₂O₄, Calculated 503.2540; observed 503.2544.

2-(3-(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-12)

White solid, 69 % yield, ¹H NMR (600 MHz, CDCl₃) δ 8.23 (dd, J= 6.6 Hz, 1.2 Hz, 1H), 8.01 (d, J= 1.8 Hz, 1H), 7.85 (dd, J= 6.6 Hz, 2.4 Hz, 1H), 7.68-7.71 (m, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.42 (t, J= 7.2 Hz, 1H), 7.12 (d, J= 8.4 Hz, 1H), 6.78 (s, 1H), 4.81 (d, J= 2.4 Hz, 2H), 3.76 (t, J= 4.2 Hz, 4H), 3.63 (s, 2H), 2.55-2.57 (m, 5H); ¹³C NMR (150 MHz, CDCl₃) δ 178.4, 163.4, 158.4, 156.2, 133.6, 128.5, 127.7, 126.4, 125.7, 125.1, 124.7, 123.9, 118.0, 112.3, 106.6, 77.9, 76.1, 67.1, 56.2, 56.1, 53.6. HRMS: m/z [M + H]⁺ for C₂₃H₂₁NO₄, Calculated 376.1543; observed 376.1546.

2-(4-(pent-4-yn-1-yloxy)-3-(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-13)

Yellowish solid, 70 % yield, ¹H NMR (600 MHz, CDCl₃) δ 8.23 (dd, J= 6.0 Hz, 1.8 Hz, 1H), 8.00 (s, 1H), 7.81 (dd, J= 6.0 Hz, 2.4 Hz, 1H), 7.67-7.70 (m, 1H), 7.57 (d, J= 7.8 Hz, 1H), 7.70-7.42 (m, 1H), 6.98 (d, J= 9.0 Hz, 1H), 6.78 (s, 1H), 4.17 (t, J= 6.6 Hz, 2H), 3.58 (s, 2H), 2.45-2.49 (m, 6H), 2.06 (quintet, J= 6.0 Hz, 2H), 2.00 (t, J= 3.0 Hz, 1H), 1.64 (t, J= 5.4 Hz, 4H), 1.47 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 178.4, 163.7, 159.8, 156.2, 133.5, 128.5, 126.4, 125.6, 125.0, 124.0, 123.7, 118.0, 111.3, 106.2, 83.2, 69.1, 66.5, 56.5, 54.6, 28.1, 26.0, 24.2, 15.2. HRMS: m/z [M + H]⁺ for C₂₆H₂₇NO₃, Calculated 402.2064; observed 402.2069.

2-(4-(pent-4-yn-1-yloxy)-3,5-bis(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-14)

White solid, 79 % yield, ¹H NMR (600 MHz, CDCl₃) δ 8.23 (dd, J= 6.0 Hz, 1.8 Hz, 1H), 7.91 (s, 2H), 7.69-7.71 (m, 1H), 7.60 (d, J= 8.4 Hz, 1H), 7.41-7.43 (m, 1H), 6.83 (s, 1H), 4.05 (t, J= 6.6 Hz, 2H), 3.54 (s, 4H), 2.50 (td, J= 4.2 Hz, 3.0 Hz, 2H), 2.45 (s, 8H), 2.04 (quintet, J= 6.6 Hz, 2H), 2.01 (t, J= 2.4 Hz, 1H), 1.60 (quintet, J= 5.4 Hz, 8H), 1.46 (s, 4H); ¹³C NMR (150 MHz, CDCl₃) δ 178.5, 163.8, 159.5, 156.3, 133.5, 133.3, 127.6, 126.9, 125.6, 125.1, 124.0, 118.1, 107.2, 83.8, 72.7, 69.0, 57.5, 54.7, 29.1, 26.1, 24.4, 15.2. HRMS: m/z [M + H]⁺ for C₃₂H₃₈N₂O₃, Calculated 499.2955; observed 499.2963.

2-(3-((benzyl(methyl)amino)methyl)-5-methoxy-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-15)

White solid, 73 % yield, ¹H NMR (600 MHz, CDCl₃) δ 8.24 (dd, J= 6.0 Hz, 1.8 Hz, 1H), 7.76 (d, J= 1.8 Hz, 1H), 7.70-7.73 (m, 1H), 7.59 (d, J= 7.8 Hz, 1H), 7.42-7.44 (m, 1H), 7.39 (d, J= 6.6 Hz, 2H), 7.33-7.35 (m, 3H), 7.25 (t, J= 7.2 Hz, 1H), 6.81 (s, 1H), 4.13 (t, J= 6.0 Hz, 2H), 3.94 (s, 3H),

3.65 (s, 2H), 3.59 (s, 2H), 2.47 (td, $J= 4.2$ Hz, 2.4 Hz, 2H), 2.24 (s, 3H), 2.00 (quintet, $J= 6.6$ Hz, 2H), 1.98 (t, $J= 3.0$ Hz, 1H), ^{13}C NMR (150 MHz, CDCl_3) δ 178.4, 163.5, 156.2, 152.9, 149.6, 139.2, 134.0, 133.6, 128.9, 128.3, 127.0, 127.0, 125.7, 125.1, 123.9, 120.9, 118.0, 108.6, 107.2, 83.8, 71.5, 68.7, 62.2, 55.9, 55.2, 42.5, 29.2, 15.2. HRMS: m/z [M + H] $^+$ for $\text{C}_{30}\text{H}_{29}\text{NO}_4$, Calculated 468.2169; observed 468.2172.

2-((4-benzylpiperazin-1-yl)methyl)-5-methoxy-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-16)

White solid, 81 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.0$ Hz, 1.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.60 (d, $J= 2.4$ Hz, 1H), 7.58 (d, $J= 8.4$ Hz, 1H), 7.41-7.44 (m, 1H), 7.33 (d, $J= 2.4$ Hz, 1H), 7.29-7.33 (m, 4H), 7.22-7.25 (m, 1H), 6.79 (s, 1H), 4.13 (t, $J= 6.0$ Hz, 2H), 3.94 (s, 3H), 3.62 (s, 2H), 3.52 (s, 2H), 2.46-2.54 (m, 10H), 2.01 (quintet, $J= 6.6$ Hz, 2H), 1.98 (t, $J= 3.0$ Hz, 1H); ^{13}C NMR (150 MHz, CDCl_3) δ 178.4, 163.4, 156.2, 153.0, 149.8, 138.2, 133.6, 133.0, 129.2, 128.1, 127.0, 126.9, 125.7, 125.2, 123.9, 121.1, 118.1, 108.8, 107.2, 83.8, 71.6, 68.7, 63.0, 56.4, 55.9, 53.2, 53.2, 29.2, 15.2. HRMS: m/z [M + H] $^+$ for $\text{C}_{33}\text{H}_{34}\text{N}_2\text{O}_4$, Calculated 523.2591; observed 523.2590.

2-(4-(but-3-yn-1-yloxy)-3-methoxy-5-((4-phenylpiperazin-1-yl)methyl)phenyl)-4H-chromen-4-one (NS-17)

White solid, 67 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (dd, $J= 6.0$ Hz, 1.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.64 (s, 1H), 7.59 (d, $J= 8.4$ Hz, 1H), 7.42-7.44 (m, 1H), 7.36 (s, 1H), 7.25-7.27 (m, 2H), 6.93 (d, $J= 7.8$ Hz, 2H), 6.85 (t, $J= 7.2$ Hz, 1H), 6.80 (s, 1H), 4.22 (t, $J= 5.4$ Hz, 2H), 3.97 (s, 3H), 3.72 (s, 2H), 3.22 (s, 4H), 2.70-2.73 (m, 6H), 2.04 (t, $J= 2.4$ Hz, 1H), ^{13}C NMR (150 MHz, CDCl_3) δ 178.3, 163.3, 156.2, 153.0, 151.3, 149.5, 133.7, 132.8, 129.1, 127.2, 125.7, 125.2, 123.9, 121.2, 119.6, 118.1, 116.0, 109.0, 107.3, 80.9, 71.1, 69.8, 56.6, 56.0, 53.1, 49.2, 20.3. HRMS: m/z [M + H] $^+$ for $\text{C}_{31}\text{H}_{30}\text{N}_2\text{O}_4$, Calculated 495.2278; observed 495.2286.

2-(3-methoxy-4-(pent-4-yn-1-yloxy)-5-((4-phenylpiperazin-1-yl)methyl)phenyl)-4H-chromen-4-one (NS-18)


White solid, 79 % yield, ^1H NMR (600 MHz, CDCl_3) δ 8.23 (d, $J= 7.8$ Hz, 1H), 7.70 (t, $J= 8.4$ Hz, 1H), 7.65 (d, $J= 1.8$ Hz, 1H), 7.58 (d, $J= 8.4$ Hz, 1H), 7.42 (t, $J= 7.8$ Hz, 1H), 7.35 (d, $J= 1.8$ Hz, 1H), 7.26 (t, $J= 8.4$ Hz, 2H), 6.93 (d, $J= 8.4$ Hz, 2H), 6.85 (t, $J= 7.8$ Hz, 1H), 6.80 (s, 1H), 4.17 (t, $J= 6.0$ Hz, 2H), 3.96 (s, 3H), 3.68 (s, $J= 2$ H), 3.23 (t, $J= 4.8$ Hz, 4H), 2.69 (t, $J= 4.2$ Hz, 4H), 2.49 (td, $J= 3.6$ Hz, 3.0 Hz, 2H), 2.03 (quintet, $J= 6.0$ Hz, 2H), 1.97 (t, $J= 2.4$ Hz, 1H); ^{13}C NMR (150


MHz, CDCl₃) δ 178.4, 163.3, 156.2, 153.1, 151.3, 149.9, 133.6, 132.8, 129.1, 127.0, 125.7, 125.2, 123.9, 121.1, 119.6, 118.1, 116.0, 108.9, 107.2, 83.8, 71.7, 68.8, 56.5, 55.9, 53.2, 49.2, 29.2, 15.2. HRMS: *m/z* [M + H]⁺ for C₃₂H₃₂N₂O₄, Calculated 509.2435; observed 509.2443.

2-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-5-methoxy-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-19)


Yellowish solid, 74 % yield, ¹H NMR (600 MHz, CDCl₃) δ 8.22 (dd, J= 6.6 Hz, 1.2 Hz, 1H), 7.72 (d, J= 2.4 Hz, 1H), 7.67-7.70 (m, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.41 (t, J= 7.2 Hz, 1H), 7.35 (d, J= 1.8 Hz, 1H), 7.09-7.14 (m, 3H), 7.00 (d, J= 7.2 Hz, 1H), 6.77 (s, 1H), 4.16 (t, J= 6.0 Hz, 2H), 3.96 (s, 3H), 3.80 (s, 2H), 3.72 (s, 2H), 2.93 (t, J= 6.0 Hz, 2H), 2.81 (t, J= 6.0 Hz, 2H), 2.47 (td, J= 4.8 Hz, 2.4 Hz, 2H), 2.01 (quintet, J= 6.6 Hz, 2H), 1.94 (t, J= 2.4 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃) δ 178.4, 163.4, 156.2, 153.1, 149.8, 134.8, 134.3, 133.6, 133.2, 128.7, 127.1, 126.5, 126.1, 125.6, 125.6, 125.1, 123.9, 121.0, 118.1, 108.9, 107.3, 83.7, 71.7, 68.7, 56.2, 56.1, 55.9, 50.8, 29.2, 29.2, 15.2. HRMS: *m/z* [M + H]⁺ for C₃₁H₂₉NO₄, Calculated 480.2169; observed 480.2177.



2-(3-methoxy-5-(morpholinomethyl)-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-1)







2-(3-methoxy-5-(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-2)








2-(4-(but-3-yn-1-yloxy)-3-methoxy-5-(morpholinomethyl)phenyl)-4H-chromen-4-one (NS-3)







2-(3-methoxy-5-(piperidin-1-ylmethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-4)








2-(3-methoxy-4-(pent-4-yn-1-yloxy)-5-(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-5)






2-(3-ethoxy-5-(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-6)





2-(4-(but-3-yn-1-yloxy)-3-ethoxy-5-(morpholinomethyl)phenyl)-4H-chromen-4-one (NS-7)



Name Inj. Vol. (uL) Rack Pos, Plate Pos, Method (Acq) Data File 1 301023_NS102_003.d

Rack Pos, Plate Pos, Method (Acq) vinod231023 low mass,m

Instrument IRM Status Success Comment


DESKTOP-7TLK19J Operator



Acq. Time (Local) 30-10-2023 17:07:43 (UTC+05:30)

+ Scan (rt: 0.327 min) 301023_NS102_003.d


Counts vs. Mass-to-Charge (m/z)


2-(3-ethoxy-5-(morpholinomethyl)-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-8)








2-(3-ethoxy-4-(pent-4-yn-1-yloxy)-5-(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-9)







2-(3,5-bis(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-10)







2-(3,5-bis(morpholinomethyl)-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-11)






2-(3-(morpholinomethyl)-4-(prop-2-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-12)







Name		Rack Pos,	Instrument	DESKTOP-7TLK193	Operator	SYSTEM (SYSTEM)
Inj. Vol. (uL)	1	Plate Pos,	IRM Status	Success		
Data File	301023_NS113_008.d	Method (Acq)	Comment		Acq. Time (Local)	30-10-2023 17:17:34 (UTC+05:30)
		vinod231023 low mass.m				






2-(4-(pent-4-yn-1-yloxy)-3-(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-13)







2-(4-(pent-4-yn-1-yloxy)-3,5-bis(piperidin-1-ylmethyl)phenyl)-4H-chromen-4-one (NS-14)








**2-((3-((benzyl(methyl)amino)methyl)-5-methoxy-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one
(NS-15)**







2-(3-((4-benzylpiperazin-1-yl)methyl)-5-methoxy-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-16)








2-(3-methoxy-4-(pent-4-yn-1-yloxy)-5-((4-phenylpiperazin-1-yl)methyl)phenyl)-4H-chromen-4-one (NS-17)





2-(3-methoxy-4-(pent-4-yn-1-yloxy)-5-((4-phenylpiperazin-1-yl)methyl)phenyl)-4H-chromen-4-one (NS-18)





2-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-5-methoxy-4-(pent-4-yn-1-yloxy)phenyl)-4H-chromen-4-one (NS-19)

